Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

The symptomatic drugs currently on the market for Alzheimer’s disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly in the last decade is immunotherapy: vaccines and, especially, passive vaccination with mono...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lannfelt, Lars, Möller, Christer, Basun, Hans, Osswald, Gunilla, Sehlin, Dag, Satlin, Andrew, Logovinsky, Veronika, Gellerfors, Pär
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4054967/
https://ncbi.nlm.nih.gov/pubmed/25031633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/alzrt246
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars